Research News

Research News Image

Innovative Fast-Fail Trial Identifies Potential New Target For Treating Anhedonia

Mar 30 2020
The National Institute of Mental Health (NIMH) established the Fast-Fail Trials program to reduce barriers to developing new psychiatric treatments. A fast-fail trial allows researchers to quickly test a potential target for treatment before investing resources into a full drug trial. Researchers have published the results of a fast-fail trial for the first time, showing that the kappa opioid receptor (KOR) mechanism plays a role in reward and pleasure. This evidence will support the development of new treatments for anhedonia — the “loss of pleasure” that is common with many mood and anxiety disorders. To learn more, visit the NIMH website.